Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of urothelial cancer in patients presenting with microhematuria and those being monitored for recurrent non-muscle invasive bladder cancer (NMIBC).
The tests help you improve the overall patient experience, while prioritizing your time and clinical resources to optimize practice workflow and improve efficiency.
Hematuria evaluation
Cxbladder Triage is optimized for the risk stratification of urothelial cancer in patients presenting with microhematuria. The test helps de-intensify clinical work-up in patients with a low probability Cxbladder test result, reducing the need for referral and invasive procedures, while prioritizing those that require immediate care.
Featured resource
SESAUA 2025 Symposium: Cxbladder Triage - Risk Stratification for Patients with Microhematuria.
Presented by Dr Zachary Klaassen, Urologic Oncologist and Associate Professor of Urology; Wellstar MCG Health and the Georgia Cancer Center.
Dr Klaassen covers the recent inclusion of Cxbladder Triage in an amendment to the AUA Microhematuria Guideline, and the benefits Cxbladder Triage offered in reducing the burden of unnecessary cystoscopies for those with a lower risk of cancer, resulting in less patient discomfort and morbidity.
Surveillance
Cxbladder Monitor is a non-invasive surveillance alternative that can reduce the burden of repeated cystoscopy in NMIBC patients with a low risk of recurrent urothelial cancer, improving comfort and compliance.
Featured resource
Survey: Surveillance Patients Show Strong Interest in Non-Invasive Test Options.
In December 2023, using the Bladder Cancer Advocacy Network’s (BCAN’s) Patient Survey Network, we surveyed 1,507 US patients being monitored for NMIBC.
Optimize your clinical practice while improving the patient experience
The Cxbladder suite helps you prioritize your time and clinical resources on those that need it the most, streamlining practice workflow and increasing overall efficiency.
Cxbladder works for both you and the patient. Spare patients with a low probability of urothelial cancer the discomfort, anxiety and risks of an invasive procedure, while optimizing your clinical practice while delivering the best patient experience possible.
Cxbladder is a precision test that delivers exceptional performance and clinically actionable results
Cxbladder is an objective test with high sensitivity and NPV.
The Cxbladder suite is supported by an evidence portfolio that includes over 25 peer reviewed publications in leading medical journals.
Cxbladder Triage is now included in the American Urological Association (AUA) Microhematuria Guideline, the first and only UBTM recommended with supporting Level A Evidence.*
The Cxbladder suite of tests have been used by over 5,000 urologists in more than 100,000 patients.
Start your Cxbladder journey
Contact our customer service team
Learn more about the Cxbladder suite and how to implement it in your practice.
How Cxbladder works
The sampling process
Cxbladder's non-invasive urine sampling system is easy for patients to use, streamlining deployment in-clinic.
The science
Cxbladder is an objective test with high sensitivity and NPV that delivers exceptional performance and clinically actionable results. The test works at a molecular level, analyzing biomarker genes to help risk stratify urothelial cancer.
The test report
The Cxbladder test report have been developed in consultation with leading urologists and provides the patient’s Cxbladder score, alongside an interpretation of the results and an assay description.
Featured Resources
Platform Reduces Unnecessary Cystoscopies for Hematuria
Dr. Zachary Klaassen interviews Dr. John Sfakianos about implementing the Cxbladder platform for microhematuria risk stratification and bladder cancer surveillance. Dr. Sfakianos discusses how high-quality biomarkers address the longstanding need to avoid over-diagnosing patients with microhematuria, where historically everyone received cystoscopy despite most having no significant findings.
Advancing Microhematuria Evaluation: The Impact of Urinary Biomarkers and Updated Guidelines
Dr. Jay Raman and Dr. Yair Lotan sit down with Dr. Zachary Klaassen to discuss the latest developments in microhematuria evaluation. Topics include the unmet need in risk stratifying patients, the evolution of the AUA Microhematuria Guideline from 2020 to 2025, and the role of urinary biomarkers in optimizing patient care, including Cxbladder Triage, a test now included in the Guideline*.
SESAUA 2025 Symposium: Cxbladder Triage - Risk Stratification for Patients with Microhematuria
Dr. Zachary Klaassen covers the recent inclusion of Cxbladder Triage in an amendment to the AUA Microhematuria Guideline*, and the benefits Cxbladder Triage offered in reducing the burden of unnecessary cystoscopies for those with a lower risk of cancer, resulting in less patient discomfort and morbidity.
Adopting Cxbladder in your clinical practice
Implementing Cxbladder
Our team are ready to guide and support you in the deployment and use of Cxbladder. Learn more implementation.
Start your Cxbladder journey
Contact our customer service team to learn more about the Cxbladder suite and how to implement it in your practice.
Cxbladder is available around the world
Cxbladder is available in the United States, and in countries across Asia and South America. Cxbladder is also available in New Zealand, Australia, and Israel.
Latest news
Medicare Coverage Update for US Cxbladder Customers
Novitas has finalized an LCD for Genetic Testing in Oncology that removes coverage for Medicare beneficiaries for Cxbladder tests effective from April 24, 2025. In this update we discuss our response and what this means for US Cxbladder customers going forward.
Cxbladder Bulletin - April 2025
Pacific Edge invites you to read the April 2025 edition of the Cxbladder Bulletin clinician newsletter.
Cxbladder's Clinical Utility in Focus at AUA 2025
Recognition of Cxbladder’s clinical and economic value in evaluating patients presenting with hematuria is set to gain momentum at the American Urological Association’s (AUA) Annual Meeting, April 26–29 in Las Vegas.
Cxbladder Guideline Inclusion to Feature at SESAUA
The inclusion of Cxbladder Triage in a February 2025 amendment to the American Urology Association (AUA) Microhematuria Guideline is set to headline a symposium at the Annual Meeting of the Southeastern Section of the AUA (SESAUA) to be held 12-15 March in Nashville, Tennessee.
References
* Barocas DA, Lotan Y, Matulewicz RS, Raman JD, Westerman ME, Kirkby E, Pak L, Souter L. Updates to Microhematuria: AUA/SUFU Guideline (2025). J Urol. 0(0). doi: 10.1097/JU.0000000000004490.